Balaxi Pharmaceuticals Ltd Stock Price Today (NSE: BALAXI)
Fundamental Score
Balaxi Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Balaxi Pharmaceuticals Ltd share price today is ₹24.00, down 2.08% on NSE/BSE as of 3 August 2026. Balaxi Pharmaceuticals Ltd (BALAXI) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹133.05 (Cr). The 52-week high for BALAXI share price is ₹52.00 and the 52-week low is ₹15.20. At a P/E ratio of 93.70x, BALAXI is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 0.59% and a debt-to-equity ratio of 0.23.
Balaxi Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Balaxi Pharmaceuticals Ltd share price chart: 0.72% return over the past month. 52-week high ₹52.00, 52-week low ₹15.20.
Balaxi Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹24.63 | ₹24.80 | ₹23.88 | ₹23.90 | 36.56K (Cr) | |
| ₹24.80 | ₹25.50 | ₹24.00 | ₹24.51 | 45.02K (Cr) | |
| ₹24.20 | ₹24.75 | ₹24.00 | ₹24.14 | 11.77K (Cr) | |
| ₹24.02 | ₹24.79 | ₹24.00 | ₹24.44 | 22.41K (Cr) | |
| ₹24.97 | ₹24.97 | ₹24.00 | ₹24.39 | 10.77K (Cr) | |
| ₹24.42 | ₹24.49 | ₹24.00 | ₹24.47 | 14.06K (Cr) | |
| ₹24.12 | ₹24.50 | ₹23.60 | ₹24.42 | 15.53K (Cr) | |
| ₹23.58 | ₹24.20 | ₹23.50 | ₹23.58 | 19.34K (Cr) | |
| ₹23.59 | ₹24.19 | ₹23.58 | ₹24.02 | 14.58K (Cr) | |
| ₹23.01 | ₹24.50 | ₹23.00 | ₹23.67 | 49.13K (Cr) |
Balaxi Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹23.87 | ₹25.50 | ₹23.00 | ₹23.90 | +0.13% | |
| ₹27.50 | ₹27.50 | ₹22.50 | ₹23.91 | -13.05% | |
| ₹27.10 | ₹29.90 | ₹23.40 | ₹26.21 | -3.28% | |
| ₹16.03 | ₹28.63 | ₹16.03 | ₹26.63 | +66.13% | |
| ₹20.00 | ₹20.90 | ₹15.20 | ₹15.67 | -21.65% | |
| ₹25.13 | ₹25.88 | ₹19.60 | ₹19.73 | -21.49% | |
| ₹27.63 | ₹29.90 | ₹23.01 | ₹24.38 | -11.76% | |
| ₹36.95 | ₹37.22 | ₹25.86 | ₹26.87 | -27.28% | |
| ₹42.94 | ₹43.85 | ₹35.67 | ₹36.75 | -14.42% | |
| ₹43.99 | ₹45.34 | ₹40.76 | ₹42.94 | -2.39% | |
| ₹46.62 | ₹47.87 | ₹42.17 | ₹43.64 | -6.39% | |
| ₹47.11 | ₹52.00 | ₹42.56 | ₹45.85 | -2.67% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Frontier market pharma play with a brutal profit reality check.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Balaxi Pharma will close its trading window from April 1, 2026, for insiders and relatives under SEBI insider trading rules. The trading halt will last until 48 hours after audited Q4 and FY26 results are declared, with the board meeting date to follow.
CORE STORY (THE REAL GAME)
Balaxi is a micro-cap pharma play targeting frontier markets. The market narrative is built on high sales growth and geographic expansion, but recent profit declines raise concerns about execution and sustainability.
- Trading window closed ahead of FY26 results
- Recent quarterly results show -95.42% YoY profit decline
- Microcap with inherent liquidity risks
- Positive surprise in FY26 results
- New order wins in key markets
- Improvement in free cash flow
- Microcap - liquidity risk
- Negative Free Cash Flow
- Promoter holding high, but FII selling
FII reduced stake by 5.37%.
Indian pharma exports are growing, but pricing pressures and trade uncertainties remain.
Profit not converting to cash. Free Cash Flow 5Y: ₹-57.6 Cr
If Balaxi can't fix its profitability issues, the stock is dead money. Watch for margin improvement and positive FCF in the next 2 quarters.
Primary Thesis Risk
Profitability collapse will kill the growth story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Balaxi Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Balaxi Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BALAXI across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.23)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (65.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
12 factors identified
Below-Average Return on Equity (0.59%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.11%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 93.70x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-92.94%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-7.29%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (3.15% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-49.23% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-48.22% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (2.36x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-80.32 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.56%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Balaxi Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Balaxi Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
15.1/100 | ₹24.00₹24 | ₹133.05₹133.05 | 93.70Average 93.7 Average | 0.59%Poor 0.59% Poor | 3.11%Poor 3.11% Poor | 0.23Excellent 0.2 Excellent | -48.22%Poor -48.22% Poor | 3.15%Average 3.15% Average | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Balaxi Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for BALAXI — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2023 | ₹9.08 | ₹86.47 | 9.5x |
| FY 2022 | ₹9.53 | ₹121.44 | 12.7x |
| FY 2021 | ₹7.63 | ₹102.62 | 13.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Balaxi Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by BALAXI — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2023 | ₹0.50 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Balaxi Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for BALAXI — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-7.29%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-92.94%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
3.15%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-48.22%
Compounded annual net profit growth over 5 years
Balaxi Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BALAXI — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Balaxi Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Balaxi Pharmaceuticals Ltd (BALAXI) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Balaxi Pharmaceuticals Ltd
About BALAXI (Balaxi Pharmaceuticals Ltd)
Balaxi Pharmaceuticals Ltd is a dynamic and expanding player in the global pharmaceutical landscape, focusing on bridging critical healthcare gaps in emerging markets. With a stead...fast commitment to quality and accessibility, Balaxi operates as an international distributor, meticulously sourcing and delivering essential pharmaceutical products to regions often underserved by mainstream pharmaceutical companies. Beyond traditional distribution, Balaxi cultivates strong, localized partnerships, building robust supply chains and tailoring product offerings to meet the specific needs and regulatory landscapes of each market. Their comprehensive approach ensures that vital medications reach patients who need them most, improving health outcomes and fostering long-term relationships with healthcare providers and communities. The company's core strength lies in its diverse therapeutic portfolio, encompassing a wide range of treatments addressing prevalent health challenges in its target regions. From life-saving antibiotics combating infectious diseases to effective analgesics alleviating pain and suffering, and vital anti-malarial medications fighting the scourge of malaria, Balaxi's product range reflects its dedication to improving public health. Beyond pharmaceuticals, Balaxi recognizes the importance of holistic well-being, extending its reach into fast-moving consumer goods (FMCG) to provide essential daily necessities. This diversified approach allows Balaxi to cater to a broader range of needs within the communities it serves, further solidifying its role as a trusted and reliable partner. Balaxi Pharmaceuticals Ltd is driven by a vision of sustainable growth and social responsibility. The company's strategic focus on emerging markets, combined with its commitment to quality, innovation, and ethical business practices, positions it for continued success in the evolving global healthcare landscape. By fostering strong relationships with manufacturers, distributors, and local communities, Balaxi is building a robust and resilient business model that delivers value to all stakeholders. With a clear mission to improve access to essential medicines and consumer goods, Balaxi Pharmaceuticals Ltd is making a tangible difference in the lives of people across Africa, the Caribbean Islands, and Latin America.
Company Details
Corporate Events
BALAXI Share Price: Frequently Asked Questions
What is the current share price of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd (BALAXI) trades at ₹24.00 on NSE. Market cap ₹133.05 (Cr). Educational data only.
What is the P/E ratio of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd has a P/E of 93.70x vs industry average 34.89x.
What is the Bull Run score for Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd has a Bull Run score of 15.1/100 based on 25+ financial parameters.
Does Balaxi Pharmaceuticals Ltd pay dividends?
Balaxi Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd has ROE of 0.59%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd has debt-to-equity of 0.23.
Is Balaxi Pharmaceuticals Ltd a good investment?
Bull Run gives Balaxi Pharmaceuticals Ltd a score of 15.1/100. This is not investment advice — consult a SEBI-registered advisor.